Tempest Therapeutics Net Income
| TPST Stock | USD 2.36 0.05 2.16% |
As of the 15th of February 2026, Tempest Therapeutics has the Coefficient Of Variation of (512.03), variance of 73.6, and Risk Adjusted Performance of (0.15). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tempest Therapeutics, as well as the relationship between them.
Tempest Therapeutics Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -48.1 M | -50.5 M | |
| Net Loss | -25.5 M | -26.7 M | |
| Net Loss | -37.7 M | -39.5 M | |
| Net Loss | (1.35) | (1.42) | |
| Net Income Per E B T | 1.14 | 1.11 |
Tempest | Net Income | Build AI portfolio with Tempest Stock |
The evolution of Net Income for Tempest Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Tempest Therapeutics compares to historical norms and industry peers.
Latest Tempest Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Tempest Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Tempest Therapeutics financial statement analysis. It represents the amount of money remaining after all of Tempest Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Tempest Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tempest Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (41.84 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Tempest Net Income Regression Statistics
| Arithmetic Mean | (37,706,137) | |
| Coefficient Of Variation | (64.19) | |
| Mean Deviation | 17,833,726 | |
| Median | (35,709,000) | |
| Standard Deviation | 24,205,043 | |
| Sample Variance | 585.9T | |
| Range | 81.9M | |
| R-Value | (0.18) | |
| Mean Square Error | 604.3T | |
| R-Squared | 0.03 | |
| Significance | 0.49 | |
| Slope | (870,130) | |
| Total Sum of Squares | 9374.1T |
Tempest Net Income History
Other Fundumenentals of Tempest Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Tempest Therapeutics Net Income component correlations
Tempest Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Tempest Therapeutics is extremely important. It helps to project a fair market value of Tempest Stock properly, considering its historical fundamentals such as Net Income. Since Tempest Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tempest Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tempest Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Tempest introduce new products? Factors like these will boost the valuation of Tempest Therapeutics. If investors know Tempest will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Tempest Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Tempest Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Tempest Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Tempest Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Tempest Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tempest Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Tempest Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Tempest Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tempest Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tempest Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Tempest Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Tempest Therapeutics or generate 0.0% return on investment in Tempest Therapeutics over 90 days. Tempest Therapeutics is related to or competes with OnKure Therapeutics, Kezar Life, Aligos Therapeutics, Xilio Development, PDS Biotechnology, Actinium Pharmaceuticals, and Barinthus Biotherapeutics. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat... More
Tempest Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tempest Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tempest Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 52.01 | |||
| Value At Risk | (9.56) | |||
| Potential Upside | 7.62 |
Tempest Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tempest Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tempest Therapeutics' standard deviation. In reality, there are many statistical measures that can use Tempest Therapeutics historical prices to predict the future Tempest Therapeutics' volatility.| Risk Adjusted Performance | (0.15) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (2.32) | |||
| Treynor Ratio | (2.21) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Tempest Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Tempest Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (2.20) | |||
| Mean Deviation | 4.76 | |||
| Coefficient Of Variation | (512.03) | |||
| Standard Deviation | 8.58 | |||
| Variance | 73.6 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (2.32) | |||
| Treynor Ratio | (2.21) | |||
| Maximum Drawdown | 52.01 | |||
| Value At Risk | (9.56) | |||
| Potential Upside | 7.62 | |||
| Skewness | (2.62) | |||
| Kurtosis | 14.35 |
Tempest Therapeutics Backtested Returns
Tempest Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.2, which indicates the firm had a -0.2 % return per unit of risk over the last 3 months. Tempest Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Tempest Therapeutics' Risk Adjusted Performance of (0.15), coefficient of variation of (512.03), and Variance of 73.6 to confirm the risk estimate we provide. The entity has a beta of 0.76, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tempest Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tempest Therapeutics is expected to be smaller as well. At this point, Tempest Therapeutics has a negative expected return of -1.72%. Please make sure to validate Tempest Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Tempest Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.35 |
Below average predictability
Tempest Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Tempest Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tempest Therapeutics price movement. The serial correlation of 0.35 indicates that nearly 35.0% of current Tempest Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.35 | |
| Spearman Rank Test | 0.55 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Tempest Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Tempest Therapeutics reported net income of (41.84 Million). This is 112.26% lower than that of the Biotechnology sector and 159.74% lower than that of the Health Care industry. The net income for all United States stocks is 107.33% higher than that of the company.
Tempest Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tempest Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics of similar companies.Tempest Therapeutics is currently under evaluation in net income category among its peers.
Tempest Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tempest Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tempest Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Tempest Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Tempest Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Tempest Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tempest Therapeutics' value.| Shares | Atlantic Trust Group, Llc | 2025-06-30 | 260 | Sbi Securities Co Ltd | 2025-06-30 | 56.0 | Bank Of America Corp | 2025-06-30 | 33.0 | Parallel Advisors, Llc | 2025-06-30 | 18.0 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 3.0 | Jane Street Group Llc | 2025-03-31 | 0.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | Global Retirement Partners, Llc. | 2025-06-30 | 0.0 | Millennium Management Llc | 2025-03-31 | 0.0 | Sabby Management Llc | 2025-06-30 | 276.6 K | Versant Venture Management Llc | 2025-06-30 | 269.8 K |
Tempest Fundamentals
| Return On Equity | -4.05 | ||||
| Return On Asset | -0.89 | ||||
| Current Valuation | 12.47 M | ||||
| Shares Outstanding | 4.93 M | ||||
| Shares Owned By Insiders | 36.69 % | ||||
| Shares Owned By Institutions | 8.22 % | ||||
| Number Of Shares Shorted | 144.51 K | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 1.82 X | ||||
| EBITDA | (40.14 M) | ||||
| Net Income | (41.84 M) | ||||
| Cash And Equivalents | 51.62 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 15.37 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 1.43 X | ||||
| Cash Flow From Operations | (33.03 M) | ||||
| Short Ratio | 1.66 X | ||||
| Earnings Per Share | (9.73) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 24 | ||||
| Beta | -2.24 | ||||
| Market Capitalization | 11.63 M | ||||
| Total Asset | 41.49 M | ||||
| Retained Earnings | (207.11 M) | ||||
| Working Capital | 17.25 M | ||||
| Net Asset | 41.49 M |
About Tempest Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tempest Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.